LUNG Valuation

Pulmonx Corp

Add to Watchlist

Advanced Chart

3.340

+0.025(0.754%)1D

Overview
Forecast
Valuation
Earnings

LUNG Relative Valuation

LUNG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LUNG is overvalued; if below, it's undervalued.

Historical Valuation

Pulmonx Corp (LUNG) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.32 is considered Undervalued compared with the five-year average of -13.97. The fair price of Pulmonx Corp (LUNG) is between 5.90 to 56.92 according to relative valuation methord. Compared to the current price of 3.34 USD , Pulmonx Corp is Undervalued By 43.38%.

Relative Value

Fair Zone

5.90-56.92

Current Price：3.34

43.38%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.73

P/B

Median3y

2.91

Median5y

3.84

-25.67

FCF Yield

Median3y

-12.67

Median5y

-9.14

Competitors Valuation Multiple

The average P/S ratio for LUNG's competitors is 9.66, providing a benchmark for relative valuation. Pulmonx Corp Corp (LUNG) exhibits a P/S ratio of 1.32, which is -86.31% above the industry average. Given its robust revenue growth of 19.54%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap